Percheron Therapeutics Limited has released a press release.
Dosing commenced in the ATL1102 toxicology study
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Receipt of R&D Tax Incentive Payment
- First approval for ATL1102 Phase IIb DMD clinical trial
- Limb Girdle Muscular Dystrophy R2 animal study commenced
- Positive outcomes in DMD combination therapy animal study
- Antisense Therapeutics CEO announces retirement
Later from Percheron Therapeutics
- PIIb DMD trial approved in Bulgaria- UK, Australia advancing
- Chief Executive Officer and Managing Director Appointment
- First Patient Dosed in ATL1102 Phase IIb DMD Trial
- MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
- Institutional Placement and proposed Share Purchase Plan SPP
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics